|
08 June 2004
Auckland, New Zealand, 8 June 2004 – Genesis Research and Development Corporation (NZX/ASX:GEN) today announced that Dr Steve Gillis, Mr Jim McLean and Dr Douglas Williams were all re-elected for a further term at the annual meeting of shareholders. About Genesis Founded in 1994, Genesis is a New Zealand-based biotechnology company. It has built a broad genomic platform and has multiple product candidates in development, targeting immune disorders and cancer. These are backed by an extensive patent portfolio. Collaborations are maintained with Amgen Inc. (Nasdaq:AMGN), Corixa Corporation (Nasdaq:CRXA), SR Pharma plc (LSE:SPA), Jurox Pty Ltd, and AgResearch. AgriGenesis Biosciences Ltd is a wholly owned subsidiary of Genesis that is focused on using key plant cell signalling genes – novel hormones and transcription factors – to control commercial traits including growth rates and wood fibre quality in trees, nutritional content of forage grasses, flowering control, and cold tolerance. It has developed comprehensive plant EST databases including the world’s largest EST database for commercial forestry species. It has commercial collaborations with ArborGen LLC, Wrightson (NZX: WRI), HortResearch, and Landcare Research. For more information, please visit www.genesis.co.nz Media contacts: Dr J Watson, Chief Executive, Genesis Research and Development Corporation Limited, +64 9 373 5600 Allan Botica, Botica Butler Raudon, +64 9 303 3862, +64 21 400 500, allanb@botica.co.nz |